VERU-111 as an Oral Tubulin Inhibitor Suppressing Triple-Negative Breast Cancer and Evaluation of Novel Tubulin Inhibitors for Cancer Therapy
Date of Award
Doctor of Philosophy (PhD)
Wei Li, PhD
Duane D. Miller, PhD Tiffany N. Seagroves, PhD Murali M. Yallapu, PhD Junming Yue, PhD
metastasis, microtubules, proliferation, TNBC, tubulin inhibitor
Triple negative breast cancer (TNBC) has aggressive clinical features strongly associated with poorer overall prognosis and higher mortality rates relative to other molecular subtypes. FDA-approved drugs, such as paclitaxel, are effective in treating TNBC. Yet, treatment failure is commonly observed due to the development of acquired chemoresistance, which remains a clinical challenge for TNBC therapy.
Deng, Shanshan (https://orcid.org/0000-0003-4646-5885), "VERU-111 as an Oral Tubulin Inhibitor Suppressing Triple-Negative Breast Cancer and Evaluation of Novel Tubulin Inhibitors for Cancer Therapy" (2020). Theses and Dissertations (ETD). Paper 533. http://dx.doi.org/10.21007/etd.cghs.2020.0524.
Chemical and Pharmacologic Phenomena Commons, Medical Pharmacology Commons, Medicinal and Pharmaceutical Chemistry Commons, Neoplasms Commons, Pharmaceutics and Drug Design Commons